GlaxoSmithKline Pakistan Limited (PSX:GLAXO)

Pakistan flag Pakistan · Delayed Price · Currency is PKR
393.49
+13.26 (3.49%)
At close: Apr 17, 2026
Market Cap125.31B -5.4%
Revenue (ttm)65.90B +7.7%
Net Income10.03B +53.4%
EPS31.48 +53.4%
Shares Out318.47M
PE Ratio12.50
Forward PE11.01
Dividend17.00 (4.32%)
Ex-Dividend DateApr 22, 2026
Volume351,226
Average Volume555,172
Open384.00
Previous Close380.23
Day's Range381.02 - 397.00
52-Week Range293.09 - 475.00
Beta0.40
RSI67.55
Earnings DateApr 24, 2026

About GlaxoSmithKline Pakistan

GlaxoSmithKline Pakistan Limited operates as a biopharma company in Pakistan. It deals in anti-infective, dermatology, respiratory, immunology, oncology, infectious diseases, HIV, and vaccines therapy areas. The company sells its products under the Augmentin, Velosef, Amoxil, Dermovate, Clobevate, Betnovate, Calpol, and Cutivate brands. It also exports its products. The company was founded in 2001 and is headquartered in Karachi, Pakistan. GlaxoSmithKline Pakistan Limited is a subsidiary of GSK plc. [Read more]

Industry Pharmaceuticals
Sector Healthcare
Founded 2001
Employees 1,606
Stock Exchange Pakistan Stock Exchange
Ticker Symbol GLAXO
Full Company Profile

Financial Performance

In 2025, GlaxoSmithKline Pakistan's revenue was 65.90 billion, an increase of 7.70% compared to the previous year's 61.19 billion. Earnings were 10.03 billion, an increase of 53.38%.

Financial Statements